Table 2 Comparisons of clinical characteristics of pMN patients with different intensity of C3 deposit
From: Clinical implications of pathological features of primary membranous nephropathy
|  | C3 – (n = 20) | C3 1+ (n = 114) | C3 2+ (n = 186) | C3 3+ (n = 51) | P |
|---|---|---|---|---|---|
Age (year) | 53 (48–60) | 53 (40–60) | 53 (43–62) | 52 (47–61) | 0.822 |
Gender (M/F) | 11/9 | 61/53 | 98/88 | 37/14 | 0.079 |
Nephrotic syndrome, n (%) | 11 (55.0%) | 67 (58.8%) | 133 (71.5%) | 44 (86.3%) | 0.002 |
Proteinuria (g/24 h) | 3.6 (2.3–7.1) | 3.4 (2.3–5.8) | 4.0 (2.2–6.0) | 6.2 (3.5–9.6) | 0.001 |
Serum albumin (g/L) | 30.1 ± 8.7 | 29.7 ± 5.9 | 26.7 ± 5.5 | 24.4 ± 5.7 | < 0.001 |
Microscopic hematuria, n (%) | 4 (20.0%) | 59 (52.7%) | 112 (60.5%) | 33 (66.0%) | 0.002 |
Serum creatinine (μmol/L) | 62.5 (50.0–80.8) | 62 (53.7–79.3) | 66.0 (53.0–79.5) | 71.0 (62.6–93.4) | 0.048 |
eGFR (ml/min per 1.73m2) | 120.0 (99.2–143.4) | 116.9(99.9–151.2) | 115.2 (90.5–142.5) | 102.6(80.4–127.0) | 0.071 |
Anti-PLA2R antibody positivity, n (%) | 11 (55.0%) | 58 (51.3%) | 136 (73.5%) | 38 (74.5%) | < 0.001 |
Anti-PLA2R antibody level (U/mL) | 76.3 (58.2–160.7) | 97.5 (52.6–186.2) | 117.8 (50.8–235.7) | 135.3 (45.0–277.1) | 0.653 |
Anti-THSD7A antibody positivity, n(%) | 0 (0.0%) | 2 (2.2%) | 2 (1.3%) | 0 (0.0%) | 0.741 |
Hypertension, n (%) | 8 (40.0%) | 62 (54.4%) | 88 (47.3%) | 29 (56.9%) | 0.369 |
Hemoglobin (g/L) | 131.0 (119.0–144.0) | 137.5 (128.0–151.0) | 137.0 (126.0–149.0) | 133.0 (115.3–143.5) | 0.059 |